The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br J Cancer. 2003;89:959-65. [PMID: 12966408]The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. ...
survival were analysed.Results HER2-positive tumors were 14.7%(11/75)by IHC.There were significant differences in HER2-positive rates according to histological type (intestinal,23.8%;no intestinal,3.0%;P <0.05)and clinical stage (Ⅰ/Ⅱ,3.1%;Ⅲ/Ⅳ,23.3;P<0.05).The overall survival of HER2-...
METHODS: The immunohistochemical expression of Her-2/Neu was studied in 37 formalin-fixed paraffin-embedded tissue sections. RESULTS: The immunohistochemical reaction produced by the anti-HER-2/Neu antibody was positive in two cases (5.4%). CONCLUSION: The low prevalence of Her-2/Neu observed in...
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82 Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al. Studies of the HER-2/neu proto-oncogene ...
Amplification or overexpression of the HER-2/neu gene in breast cancers is associated with aggressive behavior and resistance to therapeutic regimens. The molecular mechanisms that contribute to therapeutic resistance/survival of HER-2/neu-overexpressing tumor cells have not been well defined. To determi...
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a ... PURPOSE: We investigated the safety and efficacy (response rates, time to disease progression, survival) of trastuzumab, carboplatin, gemcitabine...
The first HER-2/neu-targeted approach to reach the clinic was trastuzumab, a humanized monoclonal antibody directed against the extracellular domain of the HER-2/neu protein. Trastuzumab therapy prolongs the survival of patients with metastático HER-2/neu-overexpressing breast cancer when combined ...
negative for Bcl-2 expression (P < 0.001), positive for the epidermal growth factor receptor (P = 0.003), and a high level of p53 (P < 0.001) and Ki-67 expression (P < 0.00). The relapse rates during the follow-up period (median 56.8 months) were 14.7% for TN breast cancer and...
et al. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: Correlation with overall survival. Cancer Res. 55, 5693–5698 (1995). CAS PubMed Google Scholar Cornolti, G. et al. Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary ...
Additionally, we investigated the relationship between potential prognostic factors and long-term survival in this patient population. MATERIALS AND METHODS Study design. All of the patients who were recruited to the registHER study had HER2-positive MBC (newly diagnosed within 6 months) at the time...